International Menopause Market Expected to Reach $27.63 Billion by 2033

The international menopause market is expected to reach $27.6 billion by 2033, according to a recent analysis of Straits Research, a market research company. In 2024, the global menopause market was valued at $17.7 billion.

Menopause begins 12 months after a woman’s final period, typically between age of 45 and 55. It usually lasts seven years but can last up to 14 years.

About 6,000 women enter menopause every day in the United States, according to the Society for Women’s Health Research.

One of the most common symptoms are vasomotor symptoms – experienced by nearly 75% of menopausal women. These include hot flashes and night sweats. Other symptoms include vaginal dryness, mood swings and weight gain, all of which can result in a decline in quality of life.

As a result, about 86.9% of women have used some form of menopause treatment, according to research published in Menopause, creating an opportunity for a large market for supplements, devices and over the counter medications.

“Furthermore, early treatment can reduce the stress of high healthcare expenditure, as women facing vasomotor symptoms lead to an overall burden of USD 660 million globally,” the report states. “In addition, productivity loss accounts for an additional USD 150 million.”

Menopause can also trigger other healthcare concerns such as hypertension (75%) and osteoporosis (30%).

The high cost of menopause drugs and a growing emphasis on personalized medicine have caused women to seek alternate, over the counter treatments.

Despite an interest in finding relief, there is still a high unmet demand in the menopause market, with 75% of women remaining untreated, which may be due to women feeling embarrassed during check-ups, the World Health Organization reports.

Last month prescription discount company GoodRx reported that the cost of menopause therapies has increased 58% since 2014.

Some of the leading players in the global menopause market include Bayer AG, Dr. Reddy’s Laboratories Ltd. and Hikma Pharmaceuticals USA Inc.